APO Research
Talk to an analyst

APO RESEARCH · REPORT

Prostate Cancer Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Prostate Cancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025196 pages

Choose your research edition.

Industry ResearchProstate Cancer Drugs Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Prostate Cancer Drugs Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal Prostate Cancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Prostate Cancer Drugs Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal Prostate Cancer Drugs Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

The global Prostate Cancer Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Prostate Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Prostate Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Prostate Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Prostate Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Prostate Cancer Drugs include Takeda Pharmaceuticals, Teva Pharmaceutical, Sanofi, Johnson & Johnson, Novartis, Merck Group, GlaxoSmithKline, Amgen and AbbVie, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Prostate Cancer Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Prostate Cancer Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Prostate Cancer Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Prostate Cancer Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Prostate Cancer Drugs Segment by Company

Takeda Pharmaceuticals

Teva Pharmaceutical

Sanofi

Johnson & Johnson

Novartis

Merck Group

GlaxoSmithKline

Amgen

AbbVie

Tokai Pharmaceuticals

Spectrum Pharmaceuticals

Northwest Biotherapeutics

Janssen Pharmaceuticals

Foresee Pharmaceuticals

Ferring Pharmaceutical

Endo Pharmaceuticals

Boehringer Ingelheim

BMS

Bayer HealthCare

Astra Zeneca

Astellas Pharma

Prostate Cancer Drugs Segment by Type

Targeted Therapy

Chemotherapy

Hormonal Therapy

Immunotherapy

Prostate Cancer Drugs Segment by Application

Clinics

Hospitals

Others

Prostate Cancer Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prostate Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Prostate Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prostate Cancer Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Prostate Cancer Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Prostate Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Prostate Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Prostate Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Prostate Cancer Drugs Industry Trends Table 2. Prostate Cancer Drugs Industry Drivers Table 3. Prostate Cancer Drugs Industry Opportunities and Challenges Table 4. Prostate Cancer Drugs Industry Restraints Table 5. Global Prostate Cancer Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Prostate Cancer Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Prostate Cancer Drugs Sales by Manufacturers (K Tons) & (2021-2026) Table 8. Global Prostate Cancer Drugs Sales Market Share by Manufacturers Table 9. Global Prostate Cancer Drugs Average Sales Price (US$/Ton) of Manufacturers (2021-2026) Table 10. Global Prostate Cancer Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Prostate Cancer Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Prostate Cancer Drugs Manufacturers, Product Type & Application Table 13. Global Prostate Cancer Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Prostate Cancer Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Targeted Therapy Table 17. Major Manufacturers of Chemotherapy Table 18. Major Manufacturers of Hormonal Therapy Table 19. Major Manufacturers of Immunotherapy Table 20. Global Prostate Cancer Drugs Sales by Type 2021 VS 2025 VS 2032 (K Tons) Table 21. Global Prostate Cancer Drugs Sales by Type (2021-2026) & (K Tons) Table 22. Global Prostate Cancer Drugs Sales by Type (2027-2032) & (K Tons) Table 23. Global Prostate Cancer Drugs Sales Market Share by Type (2021-2026) Table 24. Global Prostate Cancer Drugs Sales Market Share by Type (2027-2032) Table 25. Global Prostate Cancer Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Tons) Table 26. Global Prostate Cancer Drugs Revenue by Type (2021-2026) & (K Tons) Table 27. Global Prostate Cancer Drugs Revenue by Type (2027-2032) & (K Tons) Table 28. Global Prostate Cancer Drugs Revenue Market Share by Type (2021-2026) Table 29. Global Prostate Cancer Drugs Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Clinics Table 31. Major Manufacturers of Hospitals Table 32. Major Manufacturers of Others Table 33. Global Prostate Cancer Drugs Sales by Application 2021 VS 2025 VS 2032 (K Tons) Table 34. Global Prostate Cancer Drugs Sales by Application (2021-2026) & (K Tons) Table 35. Global Prostate Cancer Drugs Sales by Application (2027-2032) & (K Tons) Table 36. Global Prostate Cancer Drugs Sales Market Share by Application (2021-2026) Table 37. Global Prostate Cancer Drugs Sales Market Share by Application (2027-2032) Table 38. Global Prostate Cancer Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Tons) Table 39. Global Prostate Cancer Drugs Revenue by Application (2021-2026) & (K Tons) Table 40. Global Prostate Cancer Drugs Revenue by Application (2027-2032) & (K Tons) Table 41. Global Prostate Cancer Drugs Revenue Market Share by Application (2021-2026) Table 42. Global Prostate Cancer Drugs Revenue Market Share by Application (2027-2032) Table 43. Global Prostate Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Tons) Table 44. Global Prostate Cancer Drugs Sales by Region (2021-2026) & (K Tons) Table 45. Global Prostate Cancer Drugs Sales Market Share by Region (2021-2026) Table 46. Global Prostate Cancer Drugs Sales Forecasted by Region (2027-2032) & (K Tons) Table 47. Global Prostate Cancer Drugs Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Prostate Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Tons) Table 49. North America Prostate Cancer Drugs Sales by Country (2021-2026) & (K Tons) Table 50. North America Prostate Cancer Drugs Sales by Country (2027-2032) & (K Tons) Table 51. Europe Prostate Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Tons) Table 52. Europe Prostate Cancer Drugs Sales by Country (2021-2026) & (K Tons) Table 53. Europe Prostate Cancer Drugs Sales by Country (2027-2032) & (K Tons) Table 54. Asia Pacific Prostate Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Tons) Table 55. Asia Pacific Prostate Cancer Drugs Sales by Country (2021-2026) & (K Tons) Table 56. Asia Pacific Prostate Cancer Drugs Sales by Country (2027-2032) & (K Tons) Table 57. South America, Middle East and Africa Prostate Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Tons) Table 58. South America, Middle East and Africa Prostate Cancer Drugs Sales by Country (2021-2026) & (K Tons) Table 59. South America, Middle East and Africa Prostate Cancer Drugs Sales by Country (2027-2032) & (K Tons) Table 60. Global Prostate Cancer Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Prostate Cancer Drugs Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Prostate Cancer Drugs Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Prostate Cancer Drugs Revenue Market Share by Region (2021-2026) Table 64. Global Prostate Cancer Drugs Revenue Market Share by Region (2027-2032) Table 65. Takeda Pharmaceuticals Company Information Table 66. Takeda Pharmaceuticals Business Overview Table 67. Takeda Pharmaceuticals Prostate Cancer Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Takeda Pharmaceuticals Prostate Cancer Drugs Product Portfolio Table 69. Takeda Pharmaceuticals Recent Development Table 70. Teva Pharmaceutical Company Information Table 71. Teva Pharmaceutical Business Overview Table 72. Teva Pharmaceutical Prostate Cancer Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Teva Pharmaceutical Prostate Cancer Drugs Product Portfolio Table 74. Teva Pharmaceutical Recent Development Table 75. Sanofi Company Information Table 76. Sanofi Business Overview Table 77. Sanofi Prostate Cancer Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Sanofi Prostate Cancer Drugs Product Portfolio Table 79. Sanofi Recent Development Table 80. Johnson & Johnson Company Information Table 81. Johnson & Johnson Business Overview Table 82. Johnson & Johnson Prostate Cancer Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Johnson & Johnson Prostate Cancer Drugs Product Portfolio Table 84. Johnson & Johnson Recent Development Table 85. Novartis Company Information Table 86. Novartis Business Overview Table 87. Novartis Prostate Cancer Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Novartis Prostate Cancer Drugs Product Portfolio Table 89. Novartis Recent Development Table 90. Merck Group Company Information Table 91. Merck Group Business Overview Table 92. Merck Group Prostate Cancer Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Merck Group Prostate Cancer Drugs Product Portfolio Table 94. Merck Group Recent Development Table 95. GlaxoSmithKline Company Information Table 96. GlaxoSmithKline Business Overview Table 97. GlaxoSmithKline Prostate Cancer Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. GlaxoSmithKline Prostate Cancer Drugs Product Portfolio Table 99. GlaxoSmithKline Recent Development Table 100. Amgen Company Information Table 101. Amgen Business Overview Table 102. Amgen Prostate Cancer Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Amgen Prostate Cancer Drugs Product Portfolio Table 104. Amgen Recent Development Table 105. AbbVie Company Information Table 106. AbbVie Business Overview Table 107. AbbVie Prostate Cancer Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. AbbVie Prostate Cancer Drugs Product Portfolio Table 109. AbbVie Recent Development Table 110. Tokai Pharmaceuticals Company Information Table 111. Tokai Pharmaceuticals Business Overview Table 112. Tokai Pharmaceuticals Prostate Cancer Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Tokai Pharmaceuticals Prostate Cancer Drugs Product Portfolio Table 114. Tokai Pharmaceuticals Recent Development Table 115. Spectrum Pharmaceuticals Company Information Table 116. Spectrum Pharmaceuticals Business Overview Table 117. Spectrum Pharmaceuticals Prostate Cancer Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Spectrum Pharmaceuticals Prostate Cancer Drugs Product Portfolio Table 119. Spectrum Pharmaceuticals Recent Development Table 120. Northwest Biotherapeutics Company Information Table 121. Northwest Biotherapeutics Business Overview Table 122. Northwest Biotherapeutics Prostate Cancer Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Northwest Biotherapeutics Prostate Cancer Drugs Product Portfolio Table 124. Northwest Biotherapeutics Recent Development Table 125. Janssen Pharmaceuticals Company Information Table 126. Janssen Pharmaceuticals Business Overview Table 127. Janssen Pharmaceuticals Prostate Cancer Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Janssen Pharmaceuticals Prostate Cancer Drugs Product Portfolio Table 129. Janssen Pharmaceuticals Recent Development Table 130. Foresee Pharmaceuticals Company Information Table 131. Foresee Pharmaceuticals Business Overview Table 132. Foresee Pharmaceuticals Prostate Cancer Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Foresee Pharmaceuticals Prostate Cancer Drugs Product Portfolio Table 134. Foresee Pharmaceuticals Recent Development Table 135. Ferring Pharmaceutical Company Information Table 136. Ferring Pharmaceutical Business Overview Table 137. Ferring Pharmaceutical Prostate Cancer Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Ferring Pharmaceutical Prostate Cancer Drugs Product Portfolio Table 139. Ferring Pharmaceutical Recent Development Table 140. Endo Pharmaceuticals Company Information Table 141. Endo Pharmaceuticals Business Overview Table 142. Endo Pharmaceuticals Prostate Cancer Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Endo Pharmaceuticals Prostate Cancer Drugs Product Portfolio Table 144. Endo Pharmaceuticals Recent Development Table 145. Boehringer Ingelheim Company Information Table 146. Boehringer Ingelheim Business Overview Table 147. Boehringer Ingelheim Prostate Cancer Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 148. Boehringer Ingelheim Prostate Cancer Drugs Product Portfolio Table 149. Boehringer Ingelheim Recent Development Table 150. BMS Company Information Table 151. BMS Business Overview Table 152. BMS Prostate Cancer Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 153. BMS Prostate Cancer Drugs Product Portfolio Table 154. BMS Recent Development Table 155. Bayer HealthCare Company Information Table 156. Bayer HealthCare Business Overview Table 157. Bayer HealthCare Prostate Cancer Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 158. Bayer HealthCare Prostate Cancer Drugs Product Portfolio Table 159. Bayer HealthCare Recent Development Table 160. Astra Zeneca Company Information Table 161. Astra Zeneca Business Overview Table 162. Astra Zeneca Prostate Cancer Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 163. Astra Zeneca Prostate Cancer Drugs Product Portfolio Table 164. Astra Zeneca Recent Development Table 165. Astellas Pharma Company Information Table 166. Astellas Pharma Business Overview Table 167. Astellas Pharma Prostate Cancer Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 168. Astellas Pharma Prostate Cancer Drugs Product Portfolio Table 169. Astellas Pharma Recent Development Table 170. Key Raw Materials Table 171. Raw Materials Key Suppliers Table 172. Prostate Cancer Drugs Distributors List Table 173. Prostate Cancer Drugs Customers List Table 174. Research Programs/Design for This Report Table 175. Authors List of This Report Table 176. Secondary Sources Table 177. Primary Sources List of Figures Figure 1. Prostate Cancer Drugs Product Image Figure 2. Global Prostate Cancer Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Prostate Cancer Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Prostate Cancer Drugs Sales (2021-2032) & (K Tons) Figure 5. Global Prostate Cancer Drugs Average Price (US$/Ton) & (2021-2032) Figure 6. Global Top 5 and 10 Prostate Cancer Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Targeted Therapy Image Figure 9. Chemotherapy Image Figure 10. Hormonal Therapy Image Figure 11. Immunotherapy Image Figure 12. Global Prostate Cancer Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Tons) Figure 13. Global Prostate Cancer Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Prostate Cancer Drugs Sales Market Share by Type (2021-2032) Figure 15. Global Prostate Cancer Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Tons) Figure 16. Global Prostate Cancer Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Prostate Cancer Drugs Revenue Market Share by Type (2021-2032) Figure 18. Clinics Image Figure 19. Hospitals Image Figure 20. Others Image Figure 21. Global Prostate Cancer Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Tons) Figure 22. Global Prostate Cancer Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Prostate Cancer Drugs Sales Market Share by Application (2021-2032) Figure 24. Global Prostate Cancer Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Tons) Figure 25. Global Prostate Cancer Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Prostate Cancer Drugs Revenue Market Share by Application (2021-2032) Figure 27. North America Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 28. North America Prostate Cancer Drugs Sales Market Share by Country (2021-2032) Figure 29. U.S. Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 30. Canada Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 31. Mexico Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 32. Europe Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 33. Europe Prostate Cancer Drugs Sales Market Share by Country (2021-2032) Figure 34. Germany Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 35. France Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 36. U.K. Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 37. Italy Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 38. Netherlands Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 39. Asia Pacific Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 40. Asia Pacific Prostate Cancer Drugs Sales Market Share by Country (2021-2032) Figure 41. China Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 42. Japan Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 43. South Korea Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 44. Southeast Asia Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 45. India Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 46. Australia Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 47. South America, Middle East and Africa Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 48. South America, Middle East and Africa Prostate Cancer Drugs Sales Market Share by Country (2021-2032) Figure 49. Brazil Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 50. South Africa Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 51. Saudi Arabia Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 52. Turkey Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 53. Argentina Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 54. UAE Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 55. Egypt Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 56. Chile Prostate Cancer Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 57. Global Prostate Cancer Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Prostate Cancer Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Prostate Cancer Drugs Revenue (2021-2032) & (US$ Million) Figure 60. North America Prostate Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Prostate Cancer Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Europe Prostate Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Prostate Cancer Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Prostate Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Prostate Cancer Drugs Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Prostate Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Prostate Cancer Drugs Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Prostate Cancer Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Targeted Therapy
  • Chemotherapy
  • Hormonal Therapy
  • Immunotherapy
Applications
  • Clinics
  • Hospitals
  • Others
Companies covered
  • Takeda Pharmaceuticals
  • Teva Pharmaceutical
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck Group
  • GlaxoSmithKline
  • Amgen
  • AbbVie
  • Tokai Pharmaceuticals
  • Spectrum Pharmaceuticals
  • Northwest Biotherapeutics
  • Janssen Pharmaceuticals
  • Foresee Pharmaceuticals
  • Ferring Pharmaceutical
  • Endo Pharmaceuticals
  • Boehringer Ingelheim
  • BMS
  • Bayer HealthCare
  • Astra Zeneca
  • Astellas Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Prostate Cancer Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Prostate Cancer Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Prostate Cancer Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Prostate Cancer Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Prostate Cancer Drugs Market Dynamics
  1. 2.1 Prostate Cancer Drugs Industry Trends
  2. 2.2 Prostate Cancer Drugs Industry Drivers
  3. 2.3 Prostate Cancer Drugs Industry Opportunities and Challenges
  4. 2.4 Prostate Cancer Drugs Industry Restraints
3 Prostate Cancer Drugs Market by Manufacturers
  1. 3.1 Global Prostate Cancer Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Prostate Cancer Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Prostate Cancer Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Prostate Cancer Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Prostate Cancer Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Prostate Cancer Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Prostate Cancer Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Prostate Cancer Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Prostate Cancer Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Prostate Cancer Drugs Tier 1, Tier 2, and Tier 3
4 Prostate Cancer Drugs Market by Type
  1. 4.1 Prostate Cancer Drugs Type Introduction
  2. 4.1.1 Targeted Therapy
  3. 4.1.2 Chemotherapy
  4. 4.1.3 Hormonal Therapy
  5. 4.1.4 Immunotherapy
  6. 4.2 Global Prostate Cancer Drugs Sales by Type
  7. 4.2.1 Global Prostate Cancer Drugs Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Prostate Cancer Drugs Sales by Type (2021-2032)
  9. 4.2.3 Global Prostate Cancer Drugs Sales Market Share by Type (2021-2032)
  10. 4.3 Global Prostate Cancer Drugs Revenue by Type
  11. 4.3.1 Global Prostate Cancer Drugs Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Prostate Cancer Drugs Revenue by Type (2021-2032)
  13. 4.3.3 Global Prostate Cancer Drugs Revenue Market Share by Type (2021-2032)
5 Prostate Cancer Drugs Market by Application
  1. 5.1 Prostate Cancer Drugs Application Introduction
  2. 5.1.1 Clinics
  3. 5.1.2 Hospitals
  4. 5.1.3 Others
  5. 5.2 Global Prostate Cancer Drugs Sales by Application
  6. 5.2.1 Global Prostate Cancer Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Prostate Cancer Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Prostate Cancer Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Prostate Cancer Drugs Revenue by Application
  10. 5.3.1 Global Prostate Cancer Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Prostate Cancer Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Prostate Cancer Drugs Revenue Market Share by Application (2021-2032)
6 Global Prostate Cancer Drugs Sales by Region
  1. 6.1 Global Prostate Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Prostate Cancer Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Prostate Cancer Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Prostate Cancer Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Prostate Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Prostate Cancer Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Prostate Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Prostate Cancer Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Prostate Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Prostate Cancer Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Prostate Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Prostate Cancer Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Prostate Cancer Drugs Revenue by Region
  1. 7.1 Global Prostate Cancer Drugs Revenue by Region
  2. 7.1.1 Global Prostate Cancer Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Prostate Cancer Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Prostate Cancer Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Prostate Cancer Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Prostate Cancer Drugs Revenue (2021-2032)
  8. 7.2.2 North America Prostate Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Prostate Cancer Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Prostate Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Prostate Cancer Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Prostate Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Prostate Cancer Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Prostate Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceuticals
  2. 8.1.1 Takeda Pharmaceuticals Company Information
  3. 8.1.2 Takeda Pharmaceuticals Business Overview
  4. 8.1.3 Takeda Pharmaceuticals Prostate Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceuticals Prostate Cancer Drugs Product Portfolio
  6. 8.1.5 Takeda Pharmaceuticals Recent Developments
  7. 8.2 Teva Pharmaceutical
  8. 8.2.1 Teva Pharmaceutical Company Information
  9. 8.2.2 Teva Pharmaceutical Business Overview
  10. 8.2.3 Teva Pharmaceutical Prostate Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Pharmaceutical Prostate Cancer Drugs Product Portfolio
  12. 8.2.5 Teva Pharmaceutical Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Prostate Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Prostate Cancer Drugs Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Johnson & Johnson
  20. 8.4.1 Johnson & Johnson Company Information
  21. 8.4.2 Johnson & Johnson Business Overview
  22. 8.4.3 Johnson & Johnson Prostate Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Prostate Cancer Drugs Product Portfolio
  24. 8.4.5 Johnson & Johnson Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Prostate Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Prostate Cancer Drugs Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Merck Group
  32. 8.6.1 Merck Group Company Information
  33. 8.6.2 Merck Group Business Overview
  34. 8.6.3 Merck Group Prostate Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck Group Prostate Cancer Drugs Product Portfolio
  36. 8.6.5 Merck Group Recent Developments
  37. 8.7 GlaxoSmithKline
  38. 8.7.1 GlaxoSmithKline Company Information
  39. 8.7.2 GlaxoSmithKline Business Overview
  40. 8.7.3 GlaxoSmithKline Prostate Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline Prostate Cancer Drugs Product Portfolio
  42. 8.7.5 GlaxoSmithKline Recent Developments
  43. 8.8 Amgen
  44. 8.8.1 Amgen Company Information
  45. 8.8.2 Amgen Business Overview
  46. 8.8.3 Amgen Prostate Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Amgen Prostate Cancer Drugs Product Portfolio
  48. 8.8.5 Amgen Recent Developments
  49. 8.9 AbbVie
  50. 8.9.1 AbbVie Company Information
  51. 8.9.2 AbbVie Business Overview
  52. 8.9.3 AbbVie Prostate Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AbbVie Prostate Cancer Drugs Product Portfolio
  54. 8.9.5 AbbVie Recent Developments
  55. 8.10 Tokai Pharmaceuticals
  56. 8.10.1 Tokai Pharmaceuticals Company Information
  57. 8.10.2 Tokai Pharmaceuticals Business Overview
  58. 8.10.3 Tokai Pharmaceuticals Prostate Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Tokai Pharmaceuticals Prostate Cancer Drugs Product Portfolio
  60. 8.10.5 Tokai Pharmaceuticals Recent Developments
  61. 8.11 Spectrum Pharmaceuticals
  62. 8.11.1 Spectrum Pharmaceuticals Company Information
  63. 8.11.2 Spectrum Pharmaceuticals Business Overview
  64. 8.11.3 Spectrum Pharmaceuticals Prostate Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Spectrum Pharmaceuticals Prostate Cancer Drugs Product Portfolio
  66. 8.11.5 Spectrum Pharmaceuticals Recent Developments
  67. 8.12 Northwest Biotherapeutics
  68. 8.12.1 Northwest Biotherapeutics Company Information
  69. 8.12.2 Northwest Biotherapeutics Business Overview
  70. 8.12.3 Northwest Biotherapeutics Prostate Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Northwest Biotherapeutics Prostate Cancer Drugs Product Portfolio
  72. 8.12.5 Northwest Biotherapeutics Recent Developments
  73. 8.13 Janssen Pharmaceuticals
  74. 8.13.1 Janssen Pharmaceuticals Company Information
  75. 8.13.2 Janssen Pharmaceuticals Business Overview
  76. 8.13.3 Janssen Pharmaceuticals Prostate Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Janssen Pharmaceuticals Prostate Cancer Drugs Product Portfolio
  78. 8.13.5 Janssen Pharmaceuticals Recent Developments
  79. 8.14 Foresee Pharmaceuticals
  80. 8.14.1 Foresee Pharmaceuticals Company Information
  81. 8.14.2 Foresee Pharmaceuticals Business Overview
  82. 8.14.3 Foresee Pharmaceuticals Prostate Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Foresee Pharmaceuticals Prostate Cancer Drugs Product Portfolio
  84. 8.14.5 Foresee Pharmaceuticals Recent Developments
  85. 8.15 Ferring Pharmaceutical
  86. 8.15.1 Ferring Pharmaceutical Company Information
  87. 8.15.2 Ferring Pharmaceutical Business Overview
  88. 8.15.3 Ferring Pharmaceutical Prostate Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Ferring Pharmaceutical Prostate Cancer Drugs Product Portfolio
  90. 8.15.5 Ferring Pharmaceutical Recent Developments
  91. 8.16 Endo Pharmaceuticals
  92. 8.16.1 Endo Pharmaceuticals Company Information
  93. 8.16.2 Endo Pharmaceuticals Business Overview
  94. 8.16.3 Endo Pharmaceuticals Prostate Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Endo Pharmaceuticals Prostate Cancer Drugs Product Portfolio
  96. 8.16.5 Endo Pharmaceuticals Recent Developments
  97. 8.17 Boehringer Ingelheim
  98. 8.17.1 Boehringer Ingelheim Company Information
  99. 8.17.2 Boehringer Ingelheim Business Overview
  100. 8.17.3 Boehringer Ingelheim Prostate Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Boehringer Ingelheim Prostate Cancer Drugs Product Portfolio
  102. 8.17.5 Boehringer Ingelheim Recent Developments
  103. 8.18 BMS
  104. 8.18.1 BMS Company Information
  105. 8.18.2 BMS Business Overview
  106. 8.18.3 BMS Prostate Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 BMS Prostate Cancer Drugs Product Portfolio
  108. 8.18.5 BMS Recent Developments
  109. 8.19 Bayer HealthCare
  110. 8.19.1 Bayer HealthCare Company Information
  111. 8.19.2 Bayer HealthCare Business Overview
  112. 8.19.3 Bayer HealthCare Prostate Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Bayer HealthCare Prostate Cancer Drugs Product Portfolio
  114. 8.19.5 Bayer HealthCare Recent Developments
  115. 8.20 Astra Zeneca
  116. 8.20.1 Astra Zeneca Company Information
  117. 8.20.2 Astra Zeneca Business Overview
  118. 8.20.3 Astra Zeneca Prostate Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Astra Zeneca Prostate Cancer Drugs Product Portfolio
  120. 8.20.5 Astra Zeneca Recent Developments
  121. 8.21 Astellas Pharma
  122. 8.21.1 Astellas Pharma Company Information
  123. 8.21.2 Astellas Pharma Business Overview
  124. 8.21.3 Astellas Pharma Prostate Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Astellas Pharma Prostate Cancer Drugs Product Portfolio
  126. 8.21.5 Astellas Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Prostate Cancer Drugs Value Chain Analysis
  2. 9.1.1 Prostate Cancer Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Prostate Cancer Drugs Production Mode & Process
  6. 9.2 Prostate Cancer Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Prostate Cancer Drugs Distributors
  9. 9.2.3 Prostate Cancer Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst